{"id":"https://openalex.org/W4385667308","doi":"https://doi.org/10.1097/01.hs9.0000971144.30344.9c","title":"P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS","display_name":"P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS","publication_year":2023,"publication_date":"2023-08-01","ids":{"openalex":"https://openalex.org/W4385667308","doi":"https://doi.org/10.1097/01.hs9.0000971144.30344.9c"},"language":"en","primary_location":{"id":"doi:10.1097/01.hs9.0000971144.30344.9c","doi":"https://doi.org/10.1097/01.hs9.0000971144.30344.9c","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000971144.30344.9c","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref","doaj"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1097/01.hs9.0000971144.30344.9c","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002133396","display_name":"Francesca Palandri","orcid":"https://orcid.org/0000-0001-8367-5668","observed_orcids":["https://orcid.org/0000-0001-8367-5668"]},"institutions":[{"id":"https://openalex.org/I9360294","display_name":"University of Bologna","ror":"https://ror.org/01111rn36","country_code":"IT","type":"education","lineage":["https://openalex.org/I9360294"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Francesca Palandri","raw_affiliation_strings":["Universita Di Bologna, Bologna, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universita Di Bologna, Bologna, Italy","institution_ids":["https://openalex.org/I9360294"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080350639","display_name":"Lucia Mas\u00e1rov\u00e1","orcid":"https://orcid.org/0000-0001-6624-4196","observed_orcids":["https://orcid.org/0000-0001-6624-4196"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lucia Masarova","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085521139","display_name":"Sr\u0111an Verstov\u0161ek","orcid":"https://orcid.org/0000-0002-6912-8569","observed_orcids":["https://orcid.org/0000-0002-6912-8569"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Srdan Verstovsek","raw_affiliation_strings":["The University of Texas MD Anderson Cancer Center, Houston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Texas MD Anderson Cancer Center, Houston, United States","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039057642","display_name":"Ruben A. Mesa","orcid":"https://orcid.org/0000-0001-5880-7972","observed_orcids":["https://orcid.org/0000-0001-5880-7972"]},"institutions":[{"id":"https://openalex.org/I1282516798","display_name":"Atrium Health Wake Forest Baptist","ror":"https://ror.org/04v8djg66","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1282516798","https://openalex.org/I47251452"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruben Mesa","raw_affiliation_strings":["Wake Health, Winston-Salem, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Wake Health, Winston-Salem, United States","institution_ids":["https://openalex.org/I1282516798"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046827092","display_name":"Claire N. Harrison","orcid":"https://orcid.org/0000-0002-3212-920X","observed_orcids":["https://orcid.org/0000-0002-3212-920X"]},"institutions":[{"id":"https://openalex.org/I200166805","display_name":"Guy's and St Thomas' NHS Foundation Trust","ror":"https://ror.org/00j161312","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I200166805"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Claire Harrison","raw_affiliation_strings":["Guys and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Guys and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom","institution_ids":["https://openalex.org/I200166805"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045788682","display_name":"Gautam Sajeev","orcid":"https://orcid.org/0000-0002-1827-8938","observed_orcids":["https://orcid.org/0000-0002-1827-8938"]},"institutions":[{"id":"https://openalex.org/I79463011","display_name":"Analysis Group (United States)","ror":"https://ror.org/044jp1563","country_code":"US","type":"company","lineage":["https://openalex.org/I79463011"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gautam Sajeev","raw_affiliation_strings":["Analysis Group, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Boston, United States","institution_ids":["https://openalex.org/I79463011"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024291639","display_name":"Boris Gorsh","orcid":"https://orcid.org/0000-0001-6977-0220","observed_orcids":["https://orcid.org/0000-0001-6977-0220"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Boris Gorsh","raw_affiliation_strings":["GSK plc, Philadelphia, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GSK plc, Philadelphia, United States","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057210334","display_name":"Ryan Simpson","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79463011","display_name":"Analysis Group (United States)","ror":"https://ror.org/044jp1563","country_code":"US","type":"company","lineage":["https://openalex.org/I79463011"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ryan Simpson","raw_affiliation_strings":["Analysis Group, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Boston, United States","institution_ids":["https://openalex.org/I79463011"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072785502","display_name":"Sang Cho","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79463011","display_name":"Analysis Group (United States)","ror":"https://ror.org/044jp1563","country_code":"US","type":"company","lineage":["https://openalex.org/I79463011"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sang Cho","raw_affiliation_strings":["Analysis Group, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Boston, United States","institution_ids":["https://openalex.org/I79463011"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100358060","display_name":"Zhaohui Wang","orcid":"https://orcid.org/0000-0003-4357-9780","observed_orcids":["https://orcid.org/0000-0003-4357-9780"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhaohui Wang","raw_affiliation_strings":["GSK plc, Philadelphia, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GSK plc, Philadelphia, United States","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028688292","display_name":"Catherine Elizabeth Ellis","orcid":"https://orcid.org/0009-0008-7635-7846","observed_orcids":["https://orcid.org/0009-0008-7635-7846"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Catherine Ellis","raw_affiliation_strings":["GSK plc, Philadelphia, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GSK plc, Philadelphia, United States","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041888491","display_name":"Sean Conlon","orcid":"https://orcid.org/0000-0003-3597-7690","observed_orcids":["https://orcid.org/0000-0003-3597-7690"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sean Conlon","raw_affiliation_strings":["GSK plc, Reading, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GSK plc, Reading, United Kingdom","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039428639","display_name":"James Signorovitch","orcid":"https://orcid.org/0000-0002-4067-8962","observed_orcids":["https://orcid.org/0000-0002-4067-8962"]},"institutions":[{"id":"https://openalex.org/I79463011","display_name":"Analysis Group (United States)","ror":"https://ror.org/044jp1563","country_code":"US","type":"company","lineage":["https://openalex.org/I79463011"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Signorovitch","raw_affiliation_strings":["Analysis Group, Boston, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Boston, United States","institution_ids":["https://openalex.org/I79463011"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":6,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":2480,"currency":"USD","value_usd":2480},"apc_paid":{"value":2480,"currency":"USD","value_usd":2480},"fwci":null,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"7","issue":"S3","first_page":"e303449c","last_page":"e303449c"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11628","display_name":"Myeloproliferative Neoplasms: Diagnosis and Treatment","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/momelotinib","display_name":"momelotinib","score":0.996999979019165},{"id":"https://openalex.org/keywords/fedratinib","display_name":"fedratinib","score":1.0},{"id":"https://openalex.org/keywords/myelofibrosis","display_name":"myelofibrosis","score":0.9919999837875366},{"id":"https://openalex.org/keywords/jak-inhibitors","display_name":"JAK inhibitors","score":0.9670000076293945},{"id":"https://openalex.org/keywords/comparative-drug-safety","display_name":"drug safety comparison","score":0.6610000133514404},{"id":"https://openalex.org/keywords/anemia","display_name":"anemia","score":0.8320000171661377},{"id":"https://openalex.org/keywords/thrombocytopenia","display_name":"thrombocytopenia","score":0.9980000257492065},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.45399999618530273},{"id":"https://openalex.org/keywords/nausea","display_name":"nausea","score":0.6060000061988831},{"id":"https://openalex.org/keywords/serious-adverse-events","display_name":"serious adverse events","score":0.6470000147819519},{"id":"https://openalex.org/keywords/matching-adjusted-indirect-comparison","display_name":"matching-adjusted indirect comparison","score":0.7670000195503235},{"id":"https://openalex.org/keywords/myeloproliferative-neoplasms","display_name":"myeloproliferative neoplasms","score":0.8130000233650208},{"id":"https://openalex.org/keywords/ruxolitinib","display_name":"ruxolitinib","score":0.6919999718666077}],"concepts":[{"id":"https://openalex.org/C2780076729","wikidata":"https://www.wikidata.org/wiki/Q1752571","display_name":"Myelofibrosis","level":3,"score":0.8941429257392883},{"id":"https://openalex.org/C2776112149","wikidata":"https://www.wikidata.org/wiki/Q7383611","display_name":"Ruxolitinib","level":4,"score":0.8725845813751221},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8266739249229431},{"id":"https://openalex.org/C2778248108","wikidata":"https://www.wikidata.org/wiki/Q5445","display_name":"Anemia","level":2,"score":0.6419922113418579},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.619102954864502},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.514854371547699},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.49200722575187683},{"id":"https://openalex.org/C77350462","wikidata":"https://www.wikidata.org/wiki/Q1125472","display_name":"Confounding","level":2,"score":0.48990339040756226},{"id":"https://openalex.org/C2780959883","wikidata":"https://www.wikidata.org/wiki/Q111146","display_name":"Hematocrit","level":2,"score":0.4472030699253082},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.4459215998649597},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.42041322588920593},{"id":"https://openalex.org/C156957248","wikidata":"https://www.wikidata.org/wiki/Q1862216","display_name":"Odds ratio","level":2,"score":0.41388195753097534},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3308272659778595},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3274979293346405},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.19209834933280945}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1097/01.hs9.0000971144.30344.9c","doi":"https://doi.org/10.1097/01.hs9.0000971144.30344.9c","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000971144.30344.9c","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:10431522","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10431522","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10431522/pdf/hs9-7-e303449c.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Hemasphere","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:c10c24e0a2514a8facb9fec41ae8ad42","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/c10c24e0a2514a8facb9fec41ae8ad42","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"HemaSphere, Vol 7, p e303449c (2023)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1097/01.hs9.0000971144.30344.9c","doi":"https://doi.org/10.1097/01.hs9.0000971144.30344.9c","is_oa":true,"landing_page_url":"https://doi.org/10.1097/01.hs9.0000971144.30344.9c","pdf_url":null,"source":{"id":"https://openalex.org/S4210211592","display_name":"HemaSphere","issn_l":"2572-9241","issn":["2572-9241"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-2","norway-1","oarl","poland-20","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310318547","host_organization_name":"Wolters Kluwer","host_organization_lineage":["https://openalex.org/P4310318547"],"host_organization_lineage_names":["Wolters Kluwer"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HemaSphere","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9943000078201294,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4385667308.pdf","grobid_xml":"https://content.openalex.org/works/W4385667308.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4386277975","https://openalex.org/W4379281842","https://openalex.org/W4411095596","https://openalex.org/W4386067397","https://openalex.org/W7204998496","https://openalex.org/W7204696523","https://openalex.org/W3112812421","https://openalex.org/W4386282175","https://openalex.org/W4402076483","https://openalex.org/W3186480219"],"abstract_inverted_index":{"Topic:":[0],"16.":[1],"Myeloproliferative":[2,464],"neoplasms":[3],"-":[4],"Clinical":[5,61],"Background:":[6],"JAK":[7],"inhibitors":[8],"(JAKi)":[9],"are":[10,80],"a":[11,72,119,431,454],"mainstay":[12],"of":[13,118,237,245,266,315,336,364,397,439,458],"myelofibrosis":[14],"(MF)":[15],"treatment,":[16],"with":[17,59,67,69,155,289,305,324,332,385,393],"proven":[18],"ability":[19],"to":[20,166,200,217,231,282,360,372,413],"improve":[21],"symptoms":[22],"and":[23,54,103,130,142,189,196,261,278,356,368,409,450,461],"spleen":[24,55,181],"volume":[25,56],"for":[26,158,222,233,240,380,426],"most":[27],"patients":[28],"(pts);":[29],"although":[30],"safety":[31,95,433],"profiles":[32],"vary,":[33],"some":[34],"approved":[35],"JAKi":[36,87],"have":[37,63],"associated":[38,331,392],"hematologic":[39,75],"toxicity.":[40],"The":[41],"JAK1/JAK2/ACVR1":[42],"inhibitor":[43],"momelotinib":[44],"(MMB)":[45],"has":[46],"shown":[47],"consistent":[48],"benefit":[49],"in":[50,57,116,136,235,293,311,320,326,387,437,443,447],"improving":[51],"anemia,":[52,271,341,402,459],"symptoms,":[53],"pts":[58],"MF.":[60],"trials":[62,105],"directly":[64],"compared":[65],"MMB":[66,70,84,102,163,253,290,306,329,381,390,429],"ruxolitinib,":[68],"showing":[71],"more":[73],"favorable":[74,425,432],"toxicity":[76],"profile.":[77],"However,":[78],"there":[79],"limited":[81],"data":[82,157,165],"comparing":[83],"vs":[85,140,148,291,307,435],"other":[86,316],"such":[88],"as":[89],"fedratinib":[90],"(FED).":[91],"Aims:":[92],"To":[93],"compare":[94,201],"outcomes":[96,125,152,317,422],"from":[97],"phase":[98],"2":[99],"and/or":[100,183],"3":[101],"FED":[104,292,325,386],"using":[106],"matching-adjusted":[107],"indirect":[108],"comparison":[109],"(MAIC).":[110],"Methods:":[111],"Adverse":[112],"events":[113],"(AEs)":[114],"occurring":[115],">10%":[117],"treatment":[120,373,414],"arm":[121],"were":[122,126,134,153,210,229,258,285,375,423],"evaluated;":[123],"primary":[124],"grade":[127,269,273,276,298,339,343,346,349,351,365,400,404,407],"3/4":[128,270,299,340,352,366,401],"anemia":[129],"thrombocytopenia.":[131],"Separate":[132],"analyses":[133,228],"performed":[135],"JAKi-naive":[137,260,312,327,449],"(SIMPLIFY-1":[138],"[S1]":[139],"JAKARTA)":[141],"JAKi-experienced":[143,263,388],"(pooled":[144],"SIMPLIFY-2":[145],"[S2],":[146],"MOMENTUM":[147],"JAKARTA2)":[149],"pts.":[150,264,313],"Evaluable":[151],"those":[154],"published":[156],"FED.":[159,383,427],"MAIC":[160],"involved":[161],"reweighting":[162],"pt":[164],"match":[167],"baseline":[168],"characteristics":[169],"prioritized":[170],"by":[171],"expert":[172],"clinical":[173,445],"input":[174],"(DIPSS/IPSS,":[175],"Total":[176],"Symptom":[177],"Score,":[178],"platelet":[179],"counts,":[180],"volume/length,":[182],"hemoglobin":[184],"levels)":[185],"between":[186,204],"trial":[187],"arms,":[188],"estimating":[190],"odds":[191],"ratios":[192],"(ORs),":[193],"risk":[194,197,335,363,396,457],"ratios,":[195],"differences":[198,234],"(RDs)":[199],"AE":[202,241,440],"rates":[203,441],"balanced":[205],"populations.":[206],"As":[207],"nonrandomized":[208],"groups":[209],"compared,":[211],"results":[212],"may":[213],"be":[214],"biased":[215],"due":[216],"unmeasured":[218],"confounding,":[219],"despite":[220],"adjusting":[221],"clinically":[223],"relevant":[224],"confounding":[225],"factors.":[226],"Sensitivity":[227],"conducted":[230],"account":[232],"lengths":[236],"follow-up":[238],"time":[239],"reporting":[242,244],"where":[243],"the":[246],"assessment":[247],"periods":[248],"was":[249,301,330,391],"unclear.":[250],"Results:":[251],"Effective":[252],"sample":[254],"sizes":[255],"after":[256],"adjustment":[257],"151.1":[259],"79.4":[262],"Odds":[265,314],"any":[267,272,275,296,337,342,345,348,398,403,406],"or":[268,297,338,399,416],"diarrhea,":[274,347,405,460],"nausea,":[277,350,408],"serious":[279,354,357,369,410],"AEs":[280,358,370,411],"leading":[281,359,371,412],"dose":[283,361,417],"reductions":[284],"statistically":[286,424],"less":[287,303],"likely":[288,304],"both":[294,376,448],"populations;":[295],"thrombocytopenia":[300,367],"also":[302,377],"FED,":[308,436],"significantly":[309,333,394,455],"so":[310],"assessed":[318],"varied":[319],"significance":[321],"(Table).":[322,419],"Compared":[323,384],"pts,":[328,389,452],"lower":[334,379,395,456],"thrombocytopenia,":[344],"AEs,":[353,355],"reduction;":[362],"discontinuation":[374,415],"numerically":[378],"than":[382],"reduction":[418],"No":[420],"identified":[421],"Summary/Conclusion:":[428],"showed":[430],"profile":[434],"terms":[438],"reported":[442],"registrational":[444],"trials,":[446],"experienced":[451],"including":[453],"nausea.":[462],"TableKeywords:":[463],"disorder,":[465],"Janus":[466],"Kinase":[467],"inhibitor,":[468],"Myelofibrosis,":[469],"Safety":[470]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-11-06T12:05:46.655746","created_date":"2023-08-09T00:00:00"}